Siroxtrin 125, 250 & 500 125mg, 250 mg & 500 mg Dispersible tablets
PDF Leaflet Revision Date: 17 June 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of chronic iron overload due to blood transfusions and non-transfusion-dependent thalassemia.
Dosage (summary)
Starting dose: 20 mg/kg for transfusion overload; 10 mg/kg for non-transfusion-dependent thalassemia.
Special Populations
- Elderly patients
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not recommended during pregnancy; breastfeeding not advised.
Key Drug Interactions
- NSAIDs
- Corticosteroids
- Oral bisphosphonates
- Anticoagulants
- Repaglinide
- CYP3A4 substrates
Contraindications
- Hypersensitivity to deferasirox
- Creatinine clearance < 60 ml/min
- Severe hepatic impairment
- Pregnancy and lactation
Common side effects
- Gastrointestinal disturbances
- Skin rash
- Increased blood creatinine
Counselling Points
- Take on an empty stomach
- Monitor for signs of GI bleeding
- Regular serum ferritin monitoring
Serious warnings
- Risk of gastrointestinal ulceration and hemorrhage
- Hepatic failure reports
- Caution in elderly patients
Important Disclaimer
The Siroxtrin 125, 250 & 500 125mg, 250 mg & 500 mg Dispersible tablets professional information leaflet below is the property of Trinity Pharma and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
